Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $27.11 Average PT from Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given a consensus rating of “Moderate Buy” by the eighteen research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have given a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $27.1111.

NTLA has been the subject of a number of research reports. Chardan Capital reduced their price target on shares of Intellia Therapeutics from $68.00 to $60.00 and set a “buy” rating for the company in a report on Monday, August 11th. Canaccord Genuity Group lowered their price objective on shares of Intellia Therapeutics from $74.00 to $54.00 and set a “buy” rating on the stock in a research report on Tuesday, June 3rd. Wedbush reissued a “neutral” rating and issued a $7.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 16th. HC Wainwright reduced their price objective on shares of Intellia Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, Wall Street Zen raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 6th.

Insider Buying and Selling at Intellia Therapeutics

In other news, Director William J. Chase purchased 100,000 shares of the company’s stock in a transaction on Wednesday, August 20th. The stock was acquired at an average price of $10.03 per share, with a total value of $1,003,000.00. Following the transaction, the director directly owned 134,693 shares of the company’s stock, valued at approximately $1,350,970.79. This represents a 288.24% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Edward J. Dulac III sold 7,462 shares of the stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total transaction of $104,617.24. Following the sale, the executive vice president directly owned 106,062 shares of the company’s stock, valued at $1,486,989.24. The trade was a 6.57% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,534 shares of company stock worth $153,837. 3.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. lifted its position in shares of Intellia Therapeutics by 51.7% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 19,726 shares of the company’s stock worth $140,000 after purchasing an additional 6,722 shares during the period. D.A. Davidson & CO. boosted its holdings in shares of Intellia Therapeutics by 76.2% in the first quarter. D.A. Davidson & CO. now owns 26,020 shares of the company’s stock worth $185,000 after buying an additional 11,250 shares during the last quarter. California State Teachers Retirement System lifted its holdings in Intellia Therapeutics by 4.1% during the fourth quarter. California State Teachers Retirement System now owns 90,638 shares of the company’s stock valued at $1,057,000 after purchasing an additional 3,596 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of Intellia Therapeutics by 84.2% in the first quarter. XTX Topco Ltd now owns 80,897 shares of the company’s stock worth $575,000 after buying an additional 36,989 shares in the last quarter. Finally, Granahan Investment Management LLC lifted its holdings in shares of Intellia Therapeutics by 55.3% in the first quarter. Granahan Investment Management LLC now owns 475,946 shares of the company’s stock worth $3,384,000 after buying an additional 169,436 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

NTLA stock opened at $16.11 on Friday. The company has a fifty day moving average price of $11.76 and a 200-day moving average price of $9.69. The company has a market capitalization of $1.73 billion, a P/E ratio of -3.43 and a beta of 2.28. Intellia Therapeutics has a 52-week low of $5.90 and a 52-week high of $23.68.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.04. The firm had revenue of $14.25 million during the quarter, compared to the consensus estimate of $12.26 million. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. During the same quarter last year, the firm earned ($1.52) earnings per share. The company’s revenue for the quarter was up 104.3% on a year-over-year basis. As a group, sell-side analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.